Aug 26, 2025
3 min read
According to the study of a large group, there is a greater but greater risk of optical neurological disorders in patients with type 2 diabetes.
According to a large coordination study, there is a low risk of optic nerve disorders with type 2 diabetes with prescribed semaglutide or tirjopotide.
Patients who have 2 diseases with Sfaghitide or Taazpt the highest development of the importance of the importance of the discovery.
This corpse class is printed in a negative opening.
"Inspects the Nan, and cared for Nan, and increre Memispher or EXTICE farmers increment."
Naion is the one who causes Optic injuries in 50.25 US, annual income expected $ 50.000 all the year.
The researchers conducted a cohort study emulating target trials using a nationwide, population-based database of US electronic health records (EHRs) spanning December 2017 to January 2023.1 Eligible participants included more than 1.5 million adults with T2D who had no prior diagnosis of eye disorders and were prescribed either semaglutide, tirzepatide, or other antidiabetic medications.
To reduce consoration, the study is similar to the score score score score score score score score score and other optical nerves and invalid routes, judging by the 2-year surveillance period.
Patients with T2D had the incidence of optical nerve disease in patients with semaglutitis or tirzepatitis compared to patients taking other antidiabetic drugs.1,76;IC 95%, 1.01-3.07).In addition, 93 patients (0.12%) experienced other optical nerve disorders in 93 treatment groups, compared to 54 patients in the control group (0.07%) (Mr, 1.65; IC 95%, 1.18-2.31).
There were no significant relationships for other optic nerve disorders or visual routes.As the absolute risk remained low, the results suggest an increase in modest but remarkable risk associated with the use of semaglutide and thyrepatide.
However, researchers recognized various research restrictions, including trusting for the EHR retrospective retryceive risks that have a paid, biased and unfavorable insecurity risks.Besides, don't let the laugh.The analysis was also limited to the SRACTX in the SRACTX network with the next 2 years, so the results may not be overall for other other wards.
Apart from these limits, researchers believe that there is a low risk in this study, but the D2D recommended semaculoid or dirgebide increased optical nervous disorders.
Researchers wrote: "To recreate these searches, to explore the underlying processes, to identify people who are exposed to this potential complication and test other eye diseases."
1 Wang L, Volkow ND, Kaelber DC, et al.semaglutid or Tirzepatid and optic nerve and visual disorders of the street in type 2.Jama Netw Open.2025; 8 (8):
2. Uu KY, Evoy F. Naily: Academy Amérika Ophthalmology August 18, 2022, Ngahontal August 18.
Keep more policy, costs and values for inspection experts at the intersection of clinical treatment and health economic care.
